Board of Directors
Steve has served as Chairman of NexEos Bio since its inception and is a founding member of the company. Steve co-founded NeXeption, Inc. in May 2011 and NeXeption, LLC in August 2012 to focus on building Biotech companies. He previously served as the Chairman of the Board of Directors of Onspira Therapeutics, Inc. from 2017 until its acquisition by Altavant Sciences in December 2019, as Chairman of Aclaris Therapeutics, Inc. (NASDAQ: ACRS), as Chairman of Ralexar Therapeutics, Inc., as Chairman, President and Chief Executive Officer of Ceptaris Therapeutics, Inc. until its acquisition by Actelion in 2013, as Chairman of Vicept Therapeutics, Inc. until its acquisition by Allergan, Inc. in July 2011. He created Ception Therapeutics, Inc. in 2005 and served as its President and Chief Executive Officer until its acquisition by Cephalon, Inc. in 2010. In 2003, Steve co-founded and served as Chief Business Officer of Trigenesis Therapeutics, Inc., acquired by Dr. Reddy’s Laboratories Inc. in 2004. He began his career at SmithKline Beecham, where he held positions of increasing responsibility in finance, sales, marketing and research and development.
He presently serves as the Vice Chairman of Life Sciences PA. Mr. Tullman is also the co-founder and board director of two IT driven companies, Zoomi, artificial intelligence for learning, and Myota, data warehouse security. Steve received a BS in Accounting from Rutgers University.
Jeff Himawan, PhD
Dr. Himawan is a Managing Director of Essex Woodlands Health Ventures (EWHV). Dr. Himawan has been at EWHV for the last 20 years, where he was a Managing Director of four funds and served on numerous public and private company boards related to EWHV's investment activity. At EWHV, Dr. Himawan primarily focused on investments in therapeutic-based, pharmaceutical assets (both small molecules and also more complex biopharmaceutical compounds) and led the firm's biotechnology practice. Through these various investments, Dr. Himawan gained an in-depth knowledge of the rapidly-growing antibody industry and the various technologies related to the discovery, manufacture, and clinical development of antibodies (both monoclonal and polyclonal).
Prior to joining EWHV, he began his venture capital career at Seed-One Ventures, an incubator fund which he co-founded in 1996. At Seed-One, he was responsible for managing all of the firm's biotech investments. EWHV invested in one of the Seed-One biotech companies, and, as a result of that interaction, Dr. Himawan joined EWHV in 1999. Prior to co-founding Seed-One, he was a bench scientist at Genzyme Corporation.
Dr. Himawan is also the founder of Point Road Foundation, which currently has a particular emphasis on environmental issues. He received a BS from the Massachusetts Institute of Technology and holds a PhD from Harvard University.
Dennis H. Langer, M.D., J.D
Dennis is currently a Director of Myriad Genetics, Inc., and several private companies. Previously, he was a Senior Vice President, Research and Development at GlaxoSmithKline and, prior to the merger of Glaxo Wellcome and SmithKline Beecham, was a Senior Vice President of SmithKline Beecham. He also served President and CEO of Neose Technologies, Inc.; President of Dr. Reddy’s Laboratories, Inc.; and also held R&D and marketing positions at G.D. Searle & Co., Abbott Laboratories and Eli Lilly & Co.
He earned a BA in Biology from Columbia University, an MD from Georgetown University School of Medicine, and a JD from Harvard Law School.
Theresa Mansi has served as Chief Executive Officer and member of the Board of Directors at NexEos since its inception in 2019. Over 30 years in the pharmaceutical and biotech industry, Theresa’s accomplishments have spanned Global Business Development, Ventures, Product Development, Strategic Marketing and Market Research. Formerly, Theresa was Vice President of the Global Business Insights division of DRG, the premier provider of healthcare data and insights. Prior to DRG, Theresa worked for GSK for more than 20 years in roles of increasing responsibility. As Senior Director Worldwide Business Development, she negotiated complex deals, closing several U.S., Japanese and European licensing and M&A deals. Theresa also headed GSK’s Ventures group where she led a team of entrepreneurs who created start-up companies with funding from a variety of sources. Early on, Theresa established GSK’s Global Marketing Research department while living in London. Theresa is a Certified Licensing Professional with an MBA in International Marketing from Saint Joseph’s University. She has completed Executive Education Programs at Darden University and the Wharton School.
Lou is President of Arrow Consulting and was recently appointed as the Chief People Officer for ISG Technologies. Additionally, he serves as a recruitment broker for a variety of Fortune 500 organizations. He previously served as Vice President, GSK Talent Solutions for GlaxoSmithKline, and had responsibility for overseeing the strategy and delivery of the global talent sourcing and recruitment functions at GSK. He originally joined SmithKline Beckman Consumer Products as Manager, Government and Public Affairs. He previously served on a variety of Boards including the U.S. Army War College, where he formerly served as Vice President of the Board, Interfaith Health & Support Services of Southern Ocean County Inc., and Robert Michael Communications, Voorhees, NJ. He is also a past trustee of the Wilkes University Board of Directors and is a former Board Member of The Executive Grapevine, an organization comprised of professionals in Talent Management, London, England. He is currently a Board Member for ISG Service Company based in Towson, MD and Arlington, TX.
Lou received his BA from St. Mary’s Seminary College and has done graduate work in the Executive Master’s Program at the University of Pennsylvania.
Chris is President and CEO of Life Sciences Pennsylvania, the life sciences industry advocacy organization for the Commonwealth of Pennsylvania. Before joining Life Sciences Pennsylvania in 2009, he served as Worldwide Vice President of Pharmaceutical Communication and Public Affairs for Johnson & Johnson. Chris currently serves as the Chairman of Aclaris Therapeutics, Inc. (NASDAQ: ACRS) and previously served as Vice President for Public Affairs at the Pharmaceutical Research and Manufacturers of America (PhRMA) and held positions at the U.S. Department of Health & Human Services and the White House. He holds a Bachelor of Arts from the College of the Holy Cross.
Dr. Siciliano is the current CEO and Co-Founder of viTToria bioTherapeutics, Inc. a cutting-edge, gene-edited cell therapy Company launched with technology developed at the University of Pennsylvania Medical School. Previously, Dr. Siciliano was the CEO and Co-Founder of Invisible Sentinel, Inc. a molecular diagnostic company that was acquired by bioMerieux, a global market leader for diagnostic testing, in February 2019. Dr. Siciliano was the inventor of Invisible Sentinel's proprietary platform technologies, veriFLOW and veriPRO, and led the company's business and R&D initiatives from the concept through acquisition.
Dr. Siciliano received a B.S. degree in Chemistry from Villanova University and shortly thereafter began his scientific career in the department of Microbiology at the University of Pennsylvania Medical School studying host-pathogens interactions. He then earned a Ph.D. in Immunology and Microbial Pathogenesis from Thomas Jefferson University where he studied antigen presentation.
Dr. Siciliano is an Entrepreneur in Residence at Agent Capital, and an advisor for Tellus bioVentures and Valley Forge Investment Group. He is the President of the Thomas Jefferson University College of Life Sciences Alumni Board. Nick also serves on several biotech start-up Advisor Boards and is a lecturer in entrepreneurship at local Universities. He holds multiple utility and design patents for diagnostic technologies and has published scientific manuscripts in the fields of bacteriology, virology, immunology, molecular biology, and cancer immunotherapy.